PSL Alliance Member Genscript explain the benefits of their new NAb Detection test for SARS-CoV-2
As the COVID-19 pandemic is slowing down globally, the attention is now moving towards people’s acquisition of immunity against the reinfection to SARS-CoV-2, which raises the importance of serological tests. In contrast to the conventional qRT-PCR test which only shows a snapshot of the current infection status, serological tests show the history of infection, hopefully providing a piece of evidence for a person’s immunity against reinfection of the virus. However, not all antibodies are capable of neutralizing the virus, and the mere presence of the antibodies against SARS-CoV-2 doesn’t necessarily mean that the person is immune to any future reinfection.
A neutralizing antibody (NAb) is an antibody that specifically binds to the positions of the virus where they are playing critical roles in the infection mechanism, thus defending a cell from a pathogen or infectious particle. Only when we examine the presence of the neutralizing antibody in a person, the immunity can be correctly measured.
cPass™ SARS-CoV-2 Neutralizing Antibody Detection kit is the only test kit capable of measuring the presence of the neutralizing antibody (NAb) in a sample. Its core technology is the Surrogate Virus Neutralization test (sVNT) invented by Dr. Linfa Wang at Duke-NUS in Singapore, and it was developed by GenScript to be available as a rapid ELISA test kit. It uses the two important proteins, human ACE2 protein and SARS-CoV-2 spike protein, which play critical roles in the infection mechanism of SARS-CoV-2. The test measures the binding capability of these two proteins in the presence of the patient’s serum to identify the presence of neutralizing antibodies in it. It is by far the only and the most accurate diagnostic test capable of forecasting a person’s immunity against the future reinfection to SARS-CoV-2.
Pandemic will eventually come to an end and assessing the immunity of a person or a population will be more and more important. cPass™ Neutralizing Antibody Detection test will likely become a new social norm in the post-COVID-19 era.
